All Journals > Infection Control and Hospital Epidemiology > January 2006 > Impact of an Infection Control Program in an ICU

Article Tools

Search for Related Articles

  • By Author
  • Search In

Highlighted Article

NHSN Annual Update:
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections

Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

Antimicrobial-resistant pathogens that cause healthcare-associated infections (HAIs) pose an ongoing and increasing challenge to hospitals, both in the clinical treatment of patients and in the prevention of the cross-transmission of these problematic pathogens.  Describing the magnitude of the problem with respect to these antimicrobial-resistant pathogens is challenging, because the levels of antimicrobial resistance vary for different types of healthcare facilities and for different geographic areas, and some resistance phenotypes are difficult for laboratories to detect. However, the findings from such attempts may help the infection control and public health communities target problems and utilize resources more efficiently.

In the News

Featured in The Times
"Ireland 'losing war' on superbug" February 15, 2009
Challenges of Implementing National Guidelines for the Control and Prevention of Methicillin‐Resistant Staphylococcus aureus Colonization or Infection in Acute Care Hospitals in the Republic of Ireland
Fidelma Fitzpatrick, MD; Fiona Roche, PhD; Robert Cunney, MB; Hilary Humphreys, MD; Strategy for the Control of Antimicrobial Resistance in Ireland Infection Control Subcommittee
The research, published in Infection Control and Hospital Epidemiology, found one third of hospitals did not have a written policy on antibiotic use, and only 35% had an antibiotic stewardship programme.

January 2006

Volume 27, Number 1
Infect Control Hosp Epidemiol 2006;27:60–66
0195-9417/2006/2701-0012$15.00
DOI: 10.1086/499150
Original Article

Impact of an Infection Control Program in an Intensive Care Unit in France

Régis Verdier, MD;

Sylvie Parer, MD;

Hélène Jean‐Pierre, MD;

Pierre Dujols, MD, PhD;

Marie‐Christine Picot, MD, PhD

Drs. Verdier, Dujols, and Picot are from the Department of Medical Information, Dr. Parer is from Intensive Care Unit A, and Dr. Jean‐Pierre is from the Department of Bacteriology, University Hospital of Montpellier, Montpellier, France.

Objective.To evaluate the impact of an infection control program in an intensive care unit (ICU).

Design.Prospective before‐after study. Two 6‐month study periods were compared; between these periods, an infection control program based on isolation was implemented.

Setting.Polyvalent ICU of Montpellier Teaching Hospital.

Patients.Any patient who was hospitalized in the ICU for >48 hours and was discharged during 1 of the 2 periods.

Main Outcome Measures.The main patient‐related variables were sex, age at admission, type of patient (surgical, medical, or trauma), Simplified Acute Physiology Score II, length of ICU stay, need for intubation, duration of exposure to invasive devices, onset of nosocomial infection and pathogens responsible, and death. We compared the 2 study periods with respect to the incidence of 4 nosocomial infections (pneumonia, urinary tract infection, bacteremia, and catheter‐associated infection), the frequency of infection with the main multidrug‐resistant pathogens, and patient survival.

Results.Patients in periods 1 and 2 were similar with regard to sex, age, physiology score, and exposure to invasive devices. The rates of infection with multidrug‐resistant pathogens were significantly lower during period 2 than during period 1 (infection rate: 28.1% of patients in period 1 and 9.6% of patients in period 2 [ ]; pneumonia rate: 32.6% of patients in period 1 and 4.2% of patients in period 2 [ ]). The mortality rate among patients with nosocomial pneumonia was 38.2% in period 1 and 4.3% in period 2 ( ).

Conclusions.After implementation of an infection control program, the rate of infection with multidrug‐resistant pathogens decreased, as did the mortality rate among patients with nosocomial pneumonia.

Received January 9, 2004; accepted April 8, 2005; electronically published January 6, 2006.

Address reprint requests to Régis Verdier, MD, CETAF, 67‐69 Avenue de Rochetaillée, 42012 Saint Etienne Cedex 02, France ().

Cited by

H. WARD, G. G. PERRON, R. C. MACLEAN. (2009) The cost of multiple drug resistance in Pseudomonas aeruginosa. Journal of Evolutionary Biology 22:5, 997-1003
Online publication date: 1-Jun-2009.
CrossRef
Close Popup